Raja Shahzad G, Benedetto Umberto, Alkizwini Eman, Gupta Sapna, Amrani Mohamed
From the Department of Cardiac Surgery, Harefield Hospital, London, United Kingdom.
Innovations (Phila). 2015 May-Jun;10(3):174-8. doi: 10.1097/IMI.0000000000000162.
Minimally invasive direct coronary artery bypass (MIDCAB) has been proposed as an attractive alternative to full sternotomy (FS) revascularization in isolated left anterior descending (LAD) artery disease not suitable for percutaneous coronary intervention. However, surgeons are still reluctant to perform MIDCAB owing to concerns about early and late outcomes. We aimed to compare short- and long-term outcomes after MIDCAB versus FS revascularization.
Prospectively collected data from institutional database were reviewed. Data for late mortality were obtained from the General Register Office. MIDCAB was performed in 318 patients, whereas 159 had FS, according to the surgeon's preference, among 477 patients with isolated LAD disease. Inverse propensity score weighting was used to estimate treatment effects on short- and long-term outcomes.
In the propensity score-adjusted analysis, FS revascularization versus MIDCAB was associated increased rate of surgical site infection [4 (2.8%) versus 1 (0.7%); P = 0.04]. The 2 groups did not significantly differ with regard to other complications including operative mortality. Mean length of hospital stay was similar for the 2 groups. After a mean follow-up time of 6.2 years (interquartile range, 3.5-9.7 years), compared to MIDCAB, FS was not associated with an improved late survival (β coef, -1.42; standard error, 1.65; P = 0.39) or risk reduction for repeat revascularization (β coef, 1.22; standard error, 1.41; P = 0.15).
MIDCAB was associated with a trend toward better short-term outcomes and excellent long-term results comparable to FS revascularization. According to these findings, surgeons should not be reluctant to perform MIDCAB in isolated LAD disease.
对于不适合经皮冠状动脉介入治疗的孤立性左前降支(LAD)动脉疾病,微创直接冠状动脉旁路移植术(MIDCAB)已被提议作为全胸骨切开术(FS)血运重建的一种有吸引力的替代方案。然而,由于对外科手术早期和晚期结果的担忧,外科医生仍然不愿意实施MIDCAB。我们旨在比较MIDCAB与FS血运重建术后的短期和长期结果。
回顾前瞻性收集的机构数据库中的数据。晚期死亡率数据来自总登记办公室。在477例孤立性LAD疾病患者中,根据外科医生的偏好,318例患者接受了MIDCAB,而159例患者接受了FS。采用逆倾向评分加权法来估计治疗对短期和长期结果的影响。
在倾向评分调整分析中,FS血运重建与MIDCAB相比,手术部位感染率增加[4例(2.8%)对1例(0.7%);P = 0.04]。两组在包括手术死亡率在内的其他并发症方面无显著差异。两组的平均住院时间相似。在平均随访6.2年(四分位间距,3.5 - 9.7年)后,与MIDCAB相比,FS与改善晚期生存率(β系数,-1.42;标准误,1.65;P = 0.39)或降低再次血运重建风险(β系数,1.22;标准误,1.41;P = 0.15)无关。
MIDCAB与短期结果更好的趋势相关,并且长期结果优异,可与FS血运重建相媲美。根据这些发现,外科医生在孤立性LAD疾病中不应不愿意实施MIDCAB。